Genetherapy agent, AMT-162 (CAS RN: 2376212–44–9),developed by UniQure Biopharma, is not yet actively recruiting butwill soon start a clinical trial, NCT06100276, to research the useof AMT-162 in patients with rapidly progressive ALS and SOD1 mutations.AMT-162, a one-time treatment, is comprised of a recombinant AAVrh10vector that expresses a miRNA targeting the SOD1 gene. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.